Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medregen LLC maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape is defined by 1 pending office action. This level of activity suggests a very targeted approach to securing intellectual property rights, with only one application currently facing active examination. This focus allows the company to dedicate its legal resources to a specific pharmaceutical or biological innovation.
The portfolio is being reviewed by 1 distinct examiner and is located within 1 distinct art unit. This indicates that the company current filings are focused on a specific niche within the biotechnology field. The lack of multiple art units or examiners suggests that the administrative complexity of the current portfolio is low, as all active matters are handled by a single group within the patent office.
BARRON, SEAN C is the busiest examiner for this portfolio, with 1 busiest examiner pending action. This individual is responsible for the entirety of the company active patent prosecution. Consequently, the success of the current filings depends on navigating the specific requirements and examination style of this one official. The busiest examiner pending count of 1 matches the total pending actions, ensuring a concentrated prosecution effort.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRON, SEAN C | 1 | 52.9% | +30.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17684959 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH AMD3100 AND TACROLIMUS | BARRON, SEAN C | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17684959 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH AMD3100 AND TACROLIMUS | BARRON, SEAN C | 1653 | §103DP | Final Rejection | 30d overdue | Pending | Mar 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial